Cancer news

The latest news in cancer research, health and policy by Cancer Research UK.

We cover developments in cancer treatments, research into cancer risk and diagnosis as well as the latest cancer science stories. You'll also find analysis and comment on health and cancer policy. 

Non Small Cell Lung Cancer

Lung cancer immunotherapy combo added to Cancer Drugs Fund

Combining an immunotherapy with chemotherapy has been recommended as a treatment for some patients with lung cancer on the NHS in England.

Kidney and lung cancer drugs approved on the NHS in Scotland

One kidney cancer treatment and two lung cancer drugs have been recommended for use on the NHS in Scotland.

Lung cancer treatment combo given initial NHS ‘no’ in England

A treatment combination has been provisionally rejected for people with certain types of lung cancer on the NHS in England.

Lung cancer immunotherapy drug approved for England

The lung cancer immunotherapy drug pembrolizumab has been made widely available on the NHS in England after a price deal was reached.

Cancer Research UK and Biotecnol to trial new immuno-oncology treatment for advanced tumours

Cancer Research UK and Biotecnol Limited will trial an experimental immuno-oncology treatment for some patients with advanced tumours.

Two clinical trials show promise with different targeted drugs for lung cancer

Two drugs targeting different gene faults in lung cancer have shown potential to be better than those already available.

Targeted drug delays relapse of intermediate-stage lung cancer

A drug holds lung cancer at bay longer after surgery than standard chemotherapy, according to unpublished results of a new trial in China.

Tracking unstable chromosomes helps predict lung cancer’s return

The first findings from the Cancer Research UK-funded TRACERx* lung cancer study show how tracking tumour evolution can help predict relapse.

Immunotherapy drug extends lives of advanced lung cancer patients

A drug that ‘reinvigorates the immune system’ can extend the lives of lung cancer patients with reduced side effects.

Achilles Therapeutics launched with funds of £13.2 million to develop immunotherapies for cancer

Syncona LLP and Cancer Research Technology (CRT) announce the formation of Achilles Therapeutics Ltd today.

Pages